Bristol Myers Squibb

BREYANZI - Cost

Updated as of: July 1st, 2024

HCPCS:

Q2054

HCPCS Code Descriptor:

Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Medicare Payment Limit:

The Breyanzi Medicare Payment Limit is $496390.205.

Average Sale Price:

BREYANZI ASP cost available once logged in.

Medicare Co-Insurance Percentage:

The Breyanzi Medicare Co-Insurance percentage is 19.796%. Breyanzi's Medicare Co-Insurance amount is $98265.405

APC Code:

The Breyanzi APC Code is: 9413

APC Payment Limit:

The APC Payment Limit for BREYANZI is available. Login to view.

Breyanzi Cost Information:

BREYANZI, a product of Bristol Myers Squibb, is aligned to HCPCS Q2054 and became effective on October 1, 2021. AWP and WAC have increased by nearly 20% through 2024. ASP increased slightly less by an estimated 5%over this time.

ACCESS PRICING AND MORE BY REGISTERING

Breyanzi’s wholesale acquisition cost (WAC) information was last updated on:
January 1, 2024
Breyanzi’s average wholesale price (AWP) information was last updated on:
January 1, 2024

Breyanzi Cost Graph: